EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Swiss Pilot Low-Dose CT Lung Cancer Screening Study: First Baseline Screening Results

Lisa Jungblut iD, Harry Etienne, Caroline Zellweger, Alessandra Matter, Miriam Patella, Thomas Frauenfelder iD, Isabelle Opitz iD

Journal of Clinical Medicine · 05.09.2023 · 12 (18) · 5771

DOI: 10.3390/jcm12185771 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.09.2023. Verfasst von Lisa Jungblut und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This pilot study conducted in Switzerland aims to assess the implementation, execution, and performance of low-dose CT lung cancer screening (LDCT-LCS). With lung cancer being the leading cause of cancer-related deaths in Switzerland, the study seeks to explore the potential impact of screening on reducing mortality rates. However, initiating a lung cancer screening program poses challenges and depends on country-specific factors. This prospective study, initiated in October 2018, enrolled participants meeting the National Lung Cancer Study criteria or a lung cancer risk above 1.5% according to the PLCOm2012 lung cancer risk-model. LDCT scans were assessed using Lung-RADS. Enrollment and follow-up are ongoing. To date, we included 112 participants, with a median age of 62 years (IQR 57–67); 42% were female. The median number of packs smoked each year was 45 (IQR 38–57), and 24% had stopped smoking before enrollment. The mean PLCOm2012 was 3.7% (±2.5%). We diagnosed lung cancer in 3.6% of participants (95%, CI:1.0–12.1%), with various stages, all treated with curative intent. The recall rate for intermediate results (Lung-RADS 3,4a) was 15%. LDCT-LCS in Switzerland, using modified inclusion criteria, is feasible. Further analysis will inform the potential implementation of a comprehensive lung cancer screening program in Switzerland.

Schlagwörter

Stichwörter der Autor:innen

computed tomographydiagnosisnon-small cell lung cancer (NSCLC)screening

Autor:innen und Institutionen

  • Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland.
  • Department of Thoracic Surgery, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland.

ORCID-Profile: Lisa Jungblut, Thomas Frauenfelder, Isabelle Opitz

Zitieren

APA

Jungblut, L., Etienne, H., Zellweger, C., Matter, A., Patella, M., Frauenfelder, T., & Opitz, I. (2023). Swiss Pilot Low-Dose CT Lung Cancer Screening Study: First Baseline Screening Results. Journal of Clinical Medicine, 12(18), 5771. https://doi.org/10.3390/jcm12185771

Vancouver

Jungblut L, Etienne H, Zellweger C, Matter A, Patella M, Frauenfelder T, et al. Swiss Pilot Low-Dose CT Lung Cancer Screening Study: First Baseline Screening Results. Journal of Clinical Medicine. 2023;12(18):5771. doi:10.3390/jcm12185771

BibTeX
@article{Jungblut2023,
  author = {Jungblut, Lisa and Etienne, Harry and Zellweger, Caroline and Matter, Alessandra and Patella, Miriam and Frauenfelder, Thomas and Opitz, Isabelle},
  title = {Swiss Pilot Low-Dose CT Lung Cancer Screening Study: First Baseline Screening Results},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {18},
  pages = {5771},
  doi = {10.3390/jcm12185771}
}
Kostenlos starten →